A Phase Ib/II, Open-label Study of LJM716 in Combination With BYL719 Compared to Taxane or Irinotecan in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Alpelisib (Primary) ; Elgemtumab (Primary) ; Docetaxel; Irinotecan; Paclitaxel
Indications Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Novartis

31 Jul 2017 This trial has been discontinued in UK-MHRA.
25 Jul 2016 Status changed from active, no longer recruiting to completed.
19 Jul 2016 This trial was completed in Belgium (end date: 3 Jun 2016) according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com